［1］中华医学会心血管病学分会.高敏心肌肌钙蛋白在急性冠状动脉综合征中的中国专家共识.中华心血管病杂志，2012，40：809.

［2］杨跃进.B型尿钠肽水平对急性心肌梗死患者心源性死亡的预测价值.中华内科杂志，2007，46：450-453.

［3］刘蓉.氨基末端脑钠肽前体对急性心肌梗死患者住院期间预后的预测价值.上海医学，2010，33：421-424.

［4］毛懿.急性心肌梗死患者血B 型利钠肽水平与心功能的相关性和诊断心力衰竭的价值，中华心血管病杂志，2006，34：425-428.

［5］毛懿，杨跃进，张健，等.急性心肌梗死后血B型尿钠肽水平与急诊经皮冠状动脉介入及远期死亡率的相关性分析.中华老年多器官疾病杂志，2009，8：541-543.

［6］Bonaca M.Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I.J Am Coll Cardiol，2010，55：2118-2124.

［7］Bonaca MP.Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes.J Am Coll Cardiol，2012，60：332-338.

［8］Decalf V.Gp Ⅱb/Ⅲa receptor antagonists in acute coronary syndromes with no ST elevation.Arch Mal Coeur Vaiss，2007，100：1006-1012.

［9］Damman P.Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome：a collaborative analysis of individual patient data from the FRISC Ⅱ（Fragmin and Fast Revascularization During Instability in Coronary Artery Disease），ICTUS（Invasive Versus Conservative Treatment in Unstable Coronary Syndromes），and RITA-3（Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction）Trials.JACC Cardiovasc Interv，2012，5：191-199.

［10］Daubert MA.The utility of troponin measurement to detect myocardial infarction：review of the current findings. Vasc Health Risk Manag，2010，6：691-699.

［11］Diercks DB，Kirk JD，Naser S，et al.Value of high-sensitivity C-reactive protein in low risk chest pain observation unit patients.Int J Emerg Med，2011，4：37.

［12］Freda BJ.Cardiac troponins in renal insufficiency：review and clinical implications.J Am Coll Cardiol，2002，40：2065-2071.

［13］Giannitsis E.High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission.Clin Chem，2010，56：642-650.

［14］Glaser R，Peacock WF，Wu AH，et al.Placental growth factor and B-type natriuretic peptide as independent predictors of risk from a multibiomarker panel in suspected acute coronary syndrome（Acute Risk and Related Outcomes Assessed With Cardiac Bio-markers ［ARROW］）study.Am J Cardiol，2011，107：821-826.

［15］Inoue K，Suwa S，Ohta H，et al.Heart fatty acid-binding protein offers similar diagnostic performance to highsensitivity tropo-nin T in emergency room patients presenting with chest pain.Circ J，2011，75：2813-2820.

［16］James SK.Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes（a GUSTO Ⅳ substudy）.Am J Cardiol，2006，97：167-172.

［17］Keller T.Sensitive troponin I assay in early diagnosis of acute myocardial infarction.N Engl J Med，2009，361：868-877.

［18］Khan SQ.C-terminal provasopressin（copeptin）as a novel and prognostic marker in acute myocardial infarction：Leicester Acute Myocardial Infarction Peptide（LAMP）study.Circulation，2007，115：2103-2110.

［19］Khan SQ.Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction：the LAMP（Leicester Acute Myocardial Infarction Peptide）study.J Am Coll Cardiol，2007，49：1525-1532.

［20］Khan SQ.Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in highrisk patients with acute ST elevation myocardial infarction.Heart，2007，93：826-831.

［21］Lindahl B.The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes.Am Heart J，2010，160：224-229.

［22］Lin RM，Fatovich DM，Grasko JM，et al.Ischaemia modified albumin cannot be used for rapid exclusion of acute coronary syndrome.Emerg Med J，2010，27：668-671.

［23］McMahon CG，Lamont JV，Curtin E，et al.Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction.Am J Emerg Med，2012，30：267-274.

［24］Newby LK.ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations：a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents.J Am Coll Cardiol，2012，60：2427-2463.

［25］Reichlin T.Early diagnosis of myocardial infarction with sensitive cardiac troponin assays.N Engl J Med，2009，361：858-867.

［26］Reichlin T，Hochholzer W，Stelzig C，et al.Incremental value of copeptin for rapid rule out of acute myocardial infarction.J Am Coll Cardiol，2009，54：60-68.

［27］Sharma R，Gaze DC，Pellerin D，et al.Evaluation of ischaemia-modified albumin as a marker of myocardial ischaemia in end-stage renal disease.Clin Sci（Lond），2007，113：25-32.

［28］Sinha MK，Vazquez JM，Calvino R，et al.Effects of balloon oc-clusion during percutaneous coronary intervention on circulating Ischemia Modified Albumin and transmyocardial lactate extrac-tion.Heart，2006，92：1852-1853.

［29］Sabatine MS.Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.Circulation，2008，117：1936-1944.

［30］Suleiman M.Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein.J Am Coll Cardiol，2006，47：962-968.

［31］Thygesen K.Universal definition of muocardial infarction.J Am Coll Cardiol 2007，50：2173-2195.

［32］Thygesen K.Recommendations for the use of cardiac troponin measurement in acute cardiac care.Eur Heart J，2010，31：2197-2204.

［33］Weber M.Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome.Am Heart J，2011，162：81-88.

［34］Windhausen F.Early invasive strategy no better than a selective invasive strategy for patients with non-ST-segment elevation acute coronary syndromes and elevated cardiac troponin T levels：long-term follow-up results of the ICTUS trial.Ned Tijdschr Geneeskd，2008，152：437-444.

［35］Wollert KC.Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome.Circulation，2007，116：1540-1548.

［36］Walter T.Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.Clin Lab，2010，56：303-309.

［37］Xu J，Kimball TR，Lorenz JN，et al.GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myo-cardium in association with SMAD protein activation.Circ Res，2006，98：342-350.

［38］Lee KK，Cipriano LE，Owens DK，et al.Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate-and low-cardiovascular-risk individuals for statin therapy.Circulation.2010，122（15）：1478-1487.

［39］Ridker PM，MacFadyen J，Libby P，et al.Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention：an Intervention Trial Evaluating Rosuvastatin（JUPITER）.Am J Cardiol.2010，106（2）：204-209.

［40］Shi B，Ni Z，Cai H，et al.High-sensitivity C-reactive protein：an independent risk factor for left ventricular hypertrophy in patients with lupus nephritis.J Biomed Biotechnol.2010，2010：373-426.

［41］Abd TT，Eapen DJ，Bajpai A，et al.The role of C-reactive protein as a risk predictor of coronary atherosclerosis：implications from the JUPITER trial.Curr Atheroscler Rep.2011，13（2）：154-161.

［42］Choudhry NK，Patrick AR，et al.The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.J Am Coll Cardiol.2011，57（7）：784-791.

［43］Jalal D，Chonchol M，Etgen T，et al.C-reactive protein as a predictor of cardiovascular events in elderly patients with chronic kidney disease.J Nephrol.2011，25（5）：719-725.

［44］Kostapanos MS，Elisaf MS.JUPITER and satellites：Clinical implications of the JUPITER study and its secondary analyses.World J Cardiol.2011，3（7）：207-214.

［45］Schoos MM，Kelbaek H，Kofoed KF，et al..Usefulness of preprocedure high-sensitivity C-reactive protein to predict death，recurrent myocardial infarction，and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention.Am J Cardiol.2011，107（11）：1597-1603.

［46］Vepsalainen T，Soinio M，Marniemi J，et al..Physical activity，high-sensitivity C-reactive protein，and total and cardiovascular disease mortality in type 2 diabetes.Diabetes Care.2011，34（7）：1492-1496.

［47］Windgassen EB，Funtowicz L，Lunsford TN，et al.C-reactive protein and high-sensitivity C-reactive protein：an update for clinicians.Postgrad Med.2011，123（1）：114-119.

［48］Goud BK，Nayal B，Devi OS，et al.Comparison of microalbuminuria with hs-CRP and low density lipoprotein levels in nondiabetic，nonhypertensive myocardial infarction patients.J Cardiovasc Dis Res.2012，3（4）：287-289.

［49］Lee KK，Cipriano LE，Owens DK，et al.Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate-and low-cardiovascular-risk individuals for statin therapy.Circulation.2010，122（15）：1478-1487.

［50］Ridker PM，MacFadyen J，Libby P，et al.Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention：an Intervention Trial Evaluating Rosuvastatin（JUPITER）.Am J Cardiol.2010，106（2）：204-209.

［51］Shi B，Ni Z，Cai H，et al.High-sensitivity C-reactive protein：an independent risk factor for left ventricular hypertrophy in patients with lupus nephritis.J Biomed Biotechnol.2010，373-426.

［52］Abd TT，Eapen DJ，Bajpai A，et al.The role of C-reactive protein as a risk predictor of coronary atherosclerosis：implications from the JUPITER trial.Curr Atheroscler Rep.2011，13（2）：154-161.

［53］Choudhry NK，Patrick AR，Glynn RJ，et al.The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.J Am Coll Cardiol.2011，57（7）：784-791.

［54］Jalal D，Chonchol M，Etgen T，et al.C-reactive protein as a predictor of cardiovascular events in elderly patients with chronic kidney disease.J Nephrol.2011，25（5）：719-725.

［55］Kostapanos MS，Elisaf MS.JUPITER and satellites：Clinical implications of the JUPITER study and its secondary analyses.World J Cardiol.2011，3（7）：207-214.

［56］Schoos MM，Kelbaek H，Kofoed KF，et al.Usefulness of preprocedure high-sensitivity C-reactive protein to predict death，recurrent myocardial infarction，and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention.Am J Cardiol.2011，107（11）：1597-1603.

［57］Vepsalainen T，Soinio M，Marniemi J，et al.Physical activity，high-sensitivity C-reactive protein，and total and cardiovascular disease mortality in type 2 diabetes.Diabetes Care.2011，34（7）：1492-1496.

［58］Windgassen EB，Funtowicz L，Lunsford TN，et al.C-reactive protein and high-sensitivity C-reactive protein：an update for clinicians.Postgrad Med.2011，123（1）：114-119.

［59］Goud BK，Nayal B，Devi OS，et al.Comparison of microalbuminuria with hs-CRP and low density lipoprotein levels in nondiabetic，nonhypertensive myocardial infarction patients.J Cardiovasc Dis Res.2012，3（4）：287-289.

［60］Achilli F，Malafronte C，Lenatti L，et al.Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI：results of the single-blind，randomized，placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction（STEM-AMI）Trial.Eur J Heart Fail，2010，12：1111-1121.

［61］Ahmadi H，Baharvand H，Ashtiani SK，et al.Safety analysis and improved cardiac function following local autologous transplantation of CD133（+）enriched bone marrow cells after myocardial infarction.Curr Neurovasc Res，2007，4：153-160.

［62］Amariglio N，Hirshberg A，Scheithauer BW，et al.Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient.PLoS Med，2009，6：e1000029.

［63］Andersen DC，Andersen P，Schneider M，et al.Murine‘cardiospheres’are not a source of stem cells with cardiomyogenic potential.Stem Cells，2009，27：1571-1581.

［64］Assmus B，Honold J，Schachinger V，et al.Transcoronary transplantation of progenitor cells after myocardial infarction.N Engl J Med，2006，355：1222-1232.

［65］Assmus B，Rolf A，Erbs S，et al.Clinical outcome 2 years after intracoronary administration of bone marrowderived progenitor cells in acute myocardial infarction.Circ Heart Fail，2010，3：89-96.

［66］Barry FP，Murphy JM，English K，et al.Immunogenicity of adult mesenchymal stem cells：lessons from the fetal allograft.Stem Cells Dev，2005，14：252-265.

［67］Bartunek J，Vanderheyden M，Vandekerckhove B，et al.Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction：feasibility and safety. Circulation，2005，112：I178-I183.

［68］Bergmann O，Bhardwaj RD，Bernard S，et al.Evidence for cardiomyocyte renewal in humans.Science，2009，324：98-102.

［69］Cao F，Lin S，Xie X，et al.In vivo visualization of embryonic stem cell survival，proliferation，and migration after cardiac delivery.Circulation，2006，113：1005-1014.

［70］Chen S，Liu Z，Tian N，et al.Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery.J Invasive Cardiol，2006，18：552-556.

［71］Chugh AR，Beache GM，Loughran JH，et al.Administration of Cardiac Stem Cells in Patients With Ischemic Cardiomyopathy：The SCIPIO Trial：Surgical Aspects and Interim Analysis of Myocardial Function and Viability by Magnetic Resonance.Circulation，2012，126：S54-64.

［72］Davis DR，Ruckdeschel Smith R，Marban E.Human cardiospheres are a source of stem cells with cardiomyogenic potential.Stem Cells，2010，28：903-904.

［73］Dawn B，Tiwari S，Kucia M，et al.Transplantation of bone marrow-derived Very Small Embryonic-Like Stem Cells attenuates left ventricular dysfunction and remodeling after myocardial infarction.Stem Cells.2008，26：1646-1655.

［74］Fischer UM，Harting MT，Jimenez F，et al.Pulmonary passage is a major obstacle for intravenous stem cell delivery：the pulmonary first-pass effect.Stem Cells Dev，2009，18：683-692.

［75］Gao LR，Wang ZG，Zhu ZM，et al.Effect of intracoronary transplantation of autologous bone marrowderived mononuclear cells on outcomes of patients with refractory chronic heart failure secondary to ischemic cardiomyopathy.Am J Cardiol，2006，98：597-602.

［76］Ge J，Li Y，Qian J，et al.Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction（TCT-STAMI）.Heart，2006，92：1764-1767.

［77］Gurdon JB，Melton DA.Nuclear reprogramming in cells.Science，2008，322：1811-1815.

［78］Hare JM，Traverse JH，Henry TD，et al.A randomized，double-blind，placebo controlled，dose-escalation study of intravenous adult human mesenchymal stem cells（prochymal）after acute myocardial infarction.J Am Coll Cardiol，2009，54：2277-2286.

［79］Hu S，Liu S，Zheng Z，et al.Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure：a single-center，randomized，double-blind，placebo-controlled clinical trial.J Am Coll Cardiol，2011，57：2409-2415.

［80］Janssens S，Dubois C，Bogaert J，et al.Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction：double-blind，randomised controlled trial.Lancet，2006，367：113-121.

［81］Jeevanantham V，Butler M，Saad A，et al.Adult bone marrow cell therapy improves survival and induces longterm improvement in cardiac parameters：a systematic review and meta-analysis.Circulation，2012，126：551-568.

［82］Johnston PV，Sasano T，Mills K，et alE.Engraftment，differentiation，and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy.Circulation，2009，120：1075-1083.

［83］Jorgensen E，Ripa RS，Helqvist S，et al.In-stent neo-intimal hyperplasia after stem cell mobilization by granulocyte-colony stimulating factor：Preliminary intracoronary ultrasound results from a double-blind randomized placebo-controlled study of patients treated with percutaneous coronary intervention for ST-elevation myocardial infarction（STEMMI Trial）.Int J Cardiol，2006，111：174-177.

［84］Kawamoto A，Iwasaki H，Kusano K，et al.CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells.Circulation，2006，114：2163-2169.

［85］Kucia M，Reca R，Campbell FR，et al.A population of very small embryonic-like（VSEL）CXCR4+SSEA-1+Oct-4+stem cells identified in adult bone marrow.Leukemia，2006，20：857-869.

［86］Kucia M，Halasa M，Wysoczynski M，et al.Morphological and molecular characterization of novel population of CXCR4（+）SSEA-4（+）Oct-4（+）very small embryonic-like cells purified from human cord blood-preliminary report.Leukemia.2007，21：297-303.

［87］Kucia M，Wu W，Ratajczak MZ，et al.Bone marrow-derived very small embryonic-like stem cells：their developmental origin and biological significance.Dev Dyn，2007，236：3309-3320.

［88］Kucia M，Wysoczynski MJ，Ratajczak J，et al.Identification of very small embryonic like（VSEL）stem cells in bone marrow.Cell Tissue Res，2007，331：125-134.

［89］Kucia MJ，Wysoczynski M，Wu W，et al.Evidence that very small embryonic-like stem cells are mobilized into peripheral blood.Stem Cells.2008，26：2083-2092.

［90］Landmesser U.Bone marrow cell therapy after myocardial infarction.What should we select？Eur Heart J，2009，30：1310-1312.

［91］Lim SY，Kim YS，Ahn YK，et al.The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model.Cardiovas Res，2006，70：530-542.

［92］Losordo DW，Schatz RA，White CJ，et al.Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina：a phase Ⅰ/Ⅱa double-blind，randomized controlled trial.Circulation，2007，115：3165-3172.

［93］Losordo DW，Henry T，Schatz RA，et al.Abstract 5638：Autologous CD34+ cell therapy for refractory angina：12 month results of the phase Ⅱ ACT34-CMI study.Circulation，2009，120：S1132.

［94］Lunde K，Solheim S，Aakhus S，et al.Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction.N Engl J Med，2006，355：1199-1209.

［95］Makkar RR，Smith RR，Cheng K，et al.Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction（CADUCEUS）：a prospective，randomised phase 1 trial.Lancet，2012，379：895-904.

［96］Mauritz C，Schwanke K，Reppel M，et al.Generation of functional murine cardiac myocytes from induced pluripotent stem cells.Circulation，2008，118：507-517.

［97］Menasche P，Hagege AA，Scorsin M，et al.Myoblast transplantation for heart failure.Lancet，2001，357：279-280.

［98］Menasche P，Alfieri O，Janssens S，et al.The Myoblast autologous grafting in ischemic cardiomyopathy（MAGIC）trial：first randomized placebo-controlled study of myoblast transplantation.Circulation，2008，117：1189-1200.

［99］Meyer GP，Wollert KC，Lotz J，et al.Intracoronary bone marrow cell transfer after myocardial infarction：eighteen months’ follow-up data from the randomized，controlled BOOST（BOne marrOw transfer to enhance ST-elevation infarct regeneration）trial.Circulation，2006，113：1287-1294.

［100］Nelson TJ，Martinez-Fernandez A，Yamada S，et al.Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells.Circulation，2009，120：408-416.

［101］Overholtzer M，Mailleux AA，Mouneimne G，et al.A nonapoptotic cell death process，entosis，that occurs by cell-in-cell invasion.Cell.2007，131：966-979.

［102］Qian H，Yang Y，Huang J，et al.Intracoronary delivery of autologous bone marrow mononuclear cells radiolabeled by 18F-fluoro-deoxy-glucose：early distribution and the effects on post-infarct hearts of swine models.J Cell Biochem，2007，102：64-74.

［103］Qian HY，Yang YJ，Huang J，et al.Effects of Tongxinluo-facilitated cellular cardiomyoplasty with autologous bone marrow-mesenchymal stem cells on post-infarct swine hearts.Chin Med J，2007，120：1416-1425.

［104］Reinecke H，Minami E，Poppa V，et al.Evidence for fusion between cardiac and skeletal muscle cells.Circ Res，2004，94：e56-e60.

［105］Ratajczak MZ，Zuba-Surma EK，Shin DM，et al.Very small embryonic-like（VSEL）stem cells in adult organs and their potential role in rejuvenation of tissues and longevity.Exp Geron，2008，43：1009-1017.

［106］Sauerzweig S，Munschc T，Leβmannc V，et al.A population of serumdeprivation-induced bone marrow stem cells（SD-BMSC）expresses marker typical for embryonic and neural stem cells .Exp Cell Res.2009，315：50-66.

［107］Schachinger V，Erbs S，Elsasser A，et al.Intracoronary bone marrow derived progenitor cells in acute myocardial infarction.N Engl J Med，2006，355：1210-1221.

［108］Schachinger V，Erbs S，Elsasser A，et al.Improved clinical outcome after intracoronary administration of bonemarrow-derived progenitor cells in acute myocardial infarction：final 1-year results of the REPAIR-AMI trial. Eur Heart J，2006，27：2775-2783.

［109］Schaefer A，Meyer GP，Fuchs M，et al.Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction：results from the BOOST trial.Eur Heart J，2006，27：929-935.

［110］Smith RR，Barile L，Cho HC，et al.Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens.Circulation，2007，115：896-908.

［111］Strauer BE，Yousef M，Schannwell CM.The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heart failure：the STAR-heart study.Eur J Heart Fail，2010，12：721-729.

［112］Takahashi K，Yamanaka S.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.Cell，2006，126：663-676.

［113］Tang YL，Tang Y，Zhang YC，et al.Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector.J Am Coll Cardiol，2005，46：1339-1350.

［114］Tendera M，Wojakowski W，Ruzyllo W，et al.Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction：results of randomized，multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction（REGENT）Trial.Eur Heart J，2009，30：1313-1321.

［115］Tse HF，Thambar S，Kwong YL，et al.Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases（PROTECT-CAD trial）.Eur Heart J，2007，28：2998-3005.

［116］Valgimigli M，Rigolin GM，Cittanti C，et al.Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans：clinical and angiographic safety profile. Eur Heart J，2005，26：1838-1845.

［117］Van derheyden M，Mansour S，Bartunek J.Accelerated atherosclerosis following intracoronary haematopoietic stem cell administration.Heart，2005，91：448.

［118］Van derheyden M，Vercauteren S，Mansour S，et al.Time-dependent effects on coronary remodeling and epicardial conductance after intracoronary injection of enriched hematopoietic bone marrow stem cells in patients with previous myocardial infarction.Cell Transplant，2007，16：919-925.

［119］Wojakowski W，Tendera M，Kucia M，et al.Mobilization of bone marrow-derived Oct-4+ SSEA-4+ Very Small Embryonic-Like Stem Cells in patients with acute myocardial infarction.J Am Coll Cardiol.2009，53：1-9.

［120］Yang YJ，Qian HY，Huang J，et al.Combined Therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts.Arterioscler Thromb Vasc Biol，2009，29：2076-2082.

［121］Yang YJ，Qian HY，Huang J，et al.Atorvastatin treatment improved post-infarction microenvironments to facilitate the survivals and activities of implanted mesenchymal stem cells in swine hearts with acute myocardial infarction and reperfusion.Eur Heart J，2008，29：1578-1590.

［122］Yoon J，Min BG，Kim YH，et al.Differentiation，engraftment and functional effects of pre-treated mesenchymal stem cells in a rat myocardial infarct model.Acta Cardiol，2005，60：277-284.

［123］Yousef M，Schannwell CM，Kostering M，et al.The BALANCE Study：clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction.J Am Coll Cardiol，2009，53：2262-2269.

［124］Zhang J，Wilson GF，Soerens AG，et al.Functional cardiomyocytes derived from human induced pluripotent stem cells.Circ Res，2009，104：e30-e41.

［125］Zohlnhofer D，Dibra A，Koppara T，et al.Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction：a meta-analysis.J Am Coll Cardiol，2008，51：1429-1437.

［126］Zuba-Surma EK，Kucia M，Abdel-Latif A，et al.Morphological characterization of very small embryonic-like stem cells（VSELs）by ImageStream system analysis J Cell Mol Med，2008，12：292-303.

［127］Ashley EA，Hershberger RE，Caleshu C et al.Genetics and cardiovascular disease：a policy statement from the American Heart Association.Circulation，2012，126（1）：142-57.

［128］Frueh FW，Amur S，Mummaneni P，Epstein RS，Aubert RE，DeLuca TM，Verbrugge RR，Burckart GJ，Lesko LJ.Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration：prevalence of related drug use.Pharmacotherapy，2008，28：992-998.

［129］Voora D，Ginsburg GS.Clinical application of cardiovascular pharmacogenetics.J Am Coll Cardiol，2012 Jul 3，60（1）：9-20.

［130］Krauss RM，Mangravite LM，Smith JD，et al.Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.Circulation，2008，117：1537-1544.

［131］Medina MW，Gao F，Ruan W，et al.Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.Circulation，2008，118：355-362.

［132］Thompson JF，Hyde CL，Wood LS，et al.Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets（TNT）cohort.Circ Cardiovasc Genet，2009，2：173-181.

［133］Voora D，Shah SH，Reed CR，et al.Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.Circ Cardiovasc Genet，2008，1：100-106.

［134］Iakoubova OA，Sabatine MS，Rowland CM，et al.Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes：results from the PROVE IT-TIMI 22 study.J Am Coll Cardiol，2008，51：449-455.

［135］Akoubova OA，Tong CH，Rowland CM，et al.Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials：the CARE and WOSCOPS trials. J Am Coll Cardiol，2008，51：435-443.

［136］Assimes TL，Ho’lm H，Kathiresan S，et al.Lack of association between the Trp719Arg polymorphism in kinesinlike protein-6 and coronary artery disease in 19 case-control studies.J Am Coll Cardiol，2010，56：1552-1563.

［137］Hopewell JC，Parish S，Clarke R，et al.No impact of KIF6 genotype on vascular risk and statin response among 18 348 randomized patients in the Heart Protection Study.J Am Coll Cardiol，2011，57：2000-2007.

［138］Ridker PM，MacFadyen JG，Glynn RJ，Chasman DI.Kinesin-Like Protein 6（KIF6）polymorphism and the efficacy of rosuvastatin in primary prevention/clinical perspective.Circ Cardiovasc Genet，2011，4：312-317.

［139］Baigent C，Keech A，Kearney PM，et al.Efficacy and safety of cholesterol-lowering treatment：prospective metaanalysis of data from 90，056 participants in 14 randomised trials of statins.Lancet，2005，366：1267-1278.

［140］Kameyama Y，Yamashita K，Kobayashi K，et al.Functional characterization of SLCO1B1（OATP-C）variants， SLCO1B1*5，SLCO1B1*15 and SLCO1B1*15+C1007G，by using transient expression systems of HeLa and HEK293 cells.Pharma-cogenet Genomics，2005，15：513-522.

［141］Link E，Parish S，Armitage J，et al.SLCO1B1 variants and statin-induced myopathy-a genomewide study.N Engl J Med，2008，359：789-799.

［142］Voora D，Shah SH，Spasojevic I，et al.The SLCO1B1*5 genetic variant is associated with statin-induced side effects.J Am Coll Cardiol，2009，54：1609-1616.

［143］Jacqueline SD，MacFadyen J，Nyberg F，et al.Lack of association between polymorphisms in the slco1b1 gene and clinical myalgia following rosuvastatin therapy.J Am Coll Cardiol，2012，59：1621.

［144］Donnelly LA，Doney ASF，Tavendale R，et al.Common nonsyn-onymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes：a Go-DARTS study.Clin Pharmacol Ther，2010，89：210-216.

［145］Gurbel PA，Bliden KP，Guyer K，et al.Platelet reactivity in patients and recurrent events post-stenting：results of the PREPARE POST-STENTING study.J Am Coll Cardiol，2005，46：1820-1826.

［146］Shuldiner AR，O’Connell JR，Bliden KP，et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA，2009，302：849-857.

［147］Breet NJ，van Werkum JW，Bouman HJ，et al.Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.JAMA，2010，303：754-762.

［148］Gladding P，Webster M，Zeng I，et al.The pharmacogenetics and pharmacodynamics of clopidogrel response：an analysis from the PRINC（Plavix Response in Coronary Intervention）trial.J Am Coll Cardiol Intv，2008，1：620-627.

［149］Brandt JT，Close SL，Iturria SJ，et al.Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmaco-dynamic response to clopidogrel but not prasugrel.J Thromb Hae-most，2007，5：2429-2436.

［150］Simon T，Bhatt DL，Bergougnan L，et al.Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.Clin Pharmacol Ther，2011，90：287-295.

［151］Mega JL，Close SL，Wiviott SD，et al.Cytochrome p-450 polymor-phisms and response to clopidogrel.N Engl J Med，2009，360：354-362.

［152］Frére C，Cuisset T，Gaborit B，et al.The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syn-drome.J Thromb Haemost，2009，7：1409-1411.

［153］Hulot JS，Wuerzner G，Bachelot-Loza C，et al.Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.J Thromb Haemost，2010，8：610-613.

［154］Pena A，Collet J-P，Hulot J-S，et al.Can we override clopidogrel resistance？Circulation，2009，119：2854-2857.

［155］Maeda A，Ando H，Asai T，et al.Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.Clin Pharmacol Ther，2011，89：229-33.

［156］Mega JL，Close SL，Wiviott SD，et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to phar-macokinetic，pharmacodynamic，and clinical outcomes.Circulation，2009，119：2553-2560.

［157］Tantry US，Bliden KP，Wei C，et al.First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel/clinical perspective.Circ Cardiovasc Genet，2010，3：556-566.

［158］Taubert D，von Beckerath N，Grimberg G，et al.Impact of P-glycoprotein on clopidogrel absorption.Clin Pharmacol Ther.2006，80：486-501.

［159］Mega JL，Close SL，Wiviott SD，et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial：a phar-macogenetic analysis. Lancet，2010，376：1312-9.

［160］Simon T，Verstuyft C，Mary-Krause M，et al.Genetic determinants of response to clopidogrel and cardiovascular events.N Engl J Med，2009，360：363-75.

［161］Collet J-P，Hulot J-S，Pena A，et al.Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myo-cardial infarction：a cohort study.Lancet 2009，373：309-17.

［162］Sibbing D，Stegherr J，Latz W，et al.Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following per-cutaneous coronary intervention.Eur Heart J，2009，30：916-22.

［163］Hulot J-S，Collet J-P，Silvain J，et al.Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration：a systematic meta-analysis.J Am Coll Cardiol，2010，56：134-43.

［164］Mega JL，Simon T，Collet J-P，et al.Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI：a meta-analysis.JAMA，2010，304：1821-1830.

［165］Sibbing D，Koch W，Gebhard D，et al.Cytochrome 2C19*17 allelic variant，platelet aggregation，bleeding events，and stent thrombosis in clopidogrel-treated patients with coronary stent placement.Circulation，2010，121：512-518.

［166］Paré G，Mehta SR，Yusuf S，et al.Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.N Engl J Med 2010，363：1704-1714.

［167］Wallentin L，James S，Storey RF，et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes：a genetic substudy of the PLATO trial.Lancet，2010，376：1320-1328.

［168］Holmes DR Jr.，Dehmer GJ，et al.ACCF/AHA clopidogrel clinical alert：approaches to the FDA “boxed warning”：a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.J Am Coll Cardiol，2010，56：321-341.

［169］CURRENT-OASIS 7 Investigators，Mehta SR，Bassand JP，et al.Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.N Engl J Med，2010，363：930-942.

［170］Price MJ，Berger PB，Teirstein PS，et al.Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention.JAMA，2011，305：1097-1105.

［171］Parodi G，Marcucci R，Valenti R，et al.High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.JAMA，2011，306：1215-1223.

［172］Cooke GE，Liu-Stratton Y，Ferketich AK，et al.Effect of platelet antigen polymorphism on platelet inhibition by aspirin，clopidogrel，or their combination.J Am Coll Cardiol，2006，47：541-546.

［173］Mathias R，Kim Y，Sung H，et al.A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease.BMC Med Genomics，2010，3：22.

［174］Faraday N，Yanek LR，Yang XP，et al.Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggre-gability and protein expression.Blood，2011，118：3367-3375.

［175］The International Warfarin Pharmacogenetics Consortium，Klein TE，Altman RB，et al.Estimation of the warfarin dose with clinical and pharmacogenetic data.N Engl J Med，2009，360：753-764.

［176］Cooper GM，Johnson JA，Langaee TY，et al.A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.Blood，2008，122：1022-1027.

［177］Schwarz UI，Ritchie MD，Bradford Y，et al.Genetic determinants of response to warfarin during initial anticoagulation.N Engl J Med，2008，358：999-1008.

［178］Zhang JE，Jorgensen AL，Alfirevic A，et al.Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy.Pharmacogenet Genomics，2009，19：781-789.

［179］Epstein RS，Moyer TP，Aubert RE，et al.Warfarin genotyping reduces hospitalization rates：results from the MM-WES（Medco-Mayo Warfarin Effectiveness Study）.J Am Coll Cardiol，2010，55：2804-2812.

［180］Gerhard T，Gong Y，Beitelshees AL，et al.Alpha-adducin polymor-phism associated with increased risk of adverse cardiovascular out-comes：results from GENEtic substudy of the International Vera-pamil SRTrandolapril Study（INVEST-GENES）.Am Heart J，2008，156：397-404.

［181］Rau T，Wuttke H，Michels LM，et al.Impact of the CYP2D6 genotype on the clinical effects of metoprolol：a prospective longitu-dinal study.Clin Pharmacol Ther，2009，85：269-272.

［182］Shin J，Johnson JA.Pharmacogenetics of beta-blockers.Pharmaco therapy，2007，27：874-887.

［183］Kurnik D，Cunningham AJ，Sofowora GG，et al.GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta（1）-adrenergic blockade in humans.Pharmacogenomics，2009，10：1581-1587.

［184］Liggett SB，Mialet-Perez J，Thaneemit-Chen S，et al.A polymorphism within a conserved beta（1）-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.Proc Natl Acad Sci，2006，103：11288-1293.

［185］Cresci S，Kelly RJ，Cappola TP，et al.Clinical and genetic modifiers of long-term survival in heart failure.J Am Coll Cardiol，2009，54：432-444.

［186］Lanfear DE，Jones PG，Marsh S，et al.Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.JAMA，2005，294：1526-1533.

［187］Liggett SB，Cresci S，Kelly RJ，et al.A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure.Nat Med，2008，14：510-517.

［188］Bijl MJ，Visser LE，van Schaik RH，et al.Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.Clin Pharmacol Ther，2009，85：45-50.

［189］WHO.Global status report on noncommunicable diseases.2010.http：//www.who.int/nmh/publications/ncd_ report2010/en/.

［190］Lloyd-Jones D，Adams R，Carnethon M，et al.Heart disease and stroke statistics-2009 update：a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation，2009，119（3）：e21-181.

［191］Ford ES，Ajani UA，Croft JB，et al.Explaining the decrease in U.S.deaths from coronary disease，1980-2000.N Engl J Med.2007，356（23）：2388-2398.

［192］Vaartjes I，O’Flaherty M，Grobbee DE，et al.Coronary heart disease mortality trends in the Netherlands 1972-2007.Heart，2011，97（7）：569-573.

［193］孙佳艺，刘静，谢学勤，等.2007至2009年北京市25岁以上居民急性冠心病事件发病率的监测.中华心血管病杂志，2012，40（3）：194-198.

［194］中华人民共和国卫生部.中国卫生统计年鉴 2010.中国协和医科大学出版社，北京，2010.

［195］卫生部心血管病防治研究中心.中国心血管病年报.2011.中国大百科出版社，北京，2012.

［196］李镒冲，王丽敏，姜勇，等.2010年中国成年人高血压患病情况.中华预防医学杂志，2012，46（5）：409-413.

［197］赵文华，张坚，由悦，等.中国18岁及以上人群血脂异常流行特点研究.中华预防医学杂志，2005，39（5）：306-310.

［198］卫生部心血管病防治研究中心.中国心血管病年报，2005.中国大百科出版社，北京，2006.

［199］Yang W，Lu J，Weng J，et al.Prevalence of diabetes among men and women in China.N Engl J Med，2010，362（12）：1090-1101.

［200］Xi B，Liang Y，He T，et al.Secular trends in the prevalence of general and abdominal obesity among Chinese adults，1993-2009.Obes Rev.2012，13（3）：287-296.

［201］Moran A，Gu D，Zhao D，et al.Future cardiovascular disease in China：markov model and risk factor scenario projections from the coronary heart disease policy model-china.Circ Cardiovasc Qual Outcomes，2010，3（3）：243-252.

［202］李贤，赵连成，李莹，等.缺血性心脑血管病10年发病预测模型的验证.中华心血管病杂志，2007，35（8）：761-764.

［203］Lloyd-Jones DM，Dyer AR，Wang R，et al.Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death（Chicago Heart Association Detection Project in Industry）.Am J Cardiol，2007，99：535-540.

［204］Berry JD，Dyer A，Cai X，et al.Lifetime risks of cardiovascular disease.N Engl J Med，2012，366：321-329.

［205］世界银行.创建健康和谐生活，遏制中国慢性病流行.2011.http：//documents.shihang.org/curated/zh/2011/ 07/15482384/toward-healthy-harmonious-life-china-stemming-rising-tide-non-communicable-diseases.

［206］方丕华.阜外心电图运动试验.北京：人民卫生出版社，2009.

［207］胡大一，郭继鸿.中国心律学2008.北京：人民卫生出版社，2008.

［208］方丕华，张澍.心电学新进展.北京：中国协和医科大学出版社，2008.

［209］卢喜烈.运动平板试验.天津：天津科学技术出版社，2004.

［210］Lewis JF，McGorray S，Lin L，et al.Exercise treadmill testing using a modified exercise protocol in women with suspected myocardial ischemia：findings from the National Heart，Lung and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation（WISE）.Am Heart J，2005，149：527-533.

［211］Higgins JP，Higgins JA.Electrocardiographic exercise stress testing：an update beyond the ST segment.Int J Cardiol，2007，116：285-299.

［212］Grzybowski A，Puchalski W，Zieba B，et al.How to improve noninvasive coronary artery disease diagnostics in premenopausal women？The influence of menstrual cycle on ST depression，left ventricle contractility，and chest pain observed during exercise echocardiography in women with angina and normal coronary angiogram.Am Heart J，2008，156（964）：e1-5.

［213］Shaw LJ，Mieres JH，Hendel RH，et al.Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with suspected coronary artery disease：results from the what is the optimal method for ischemia evaluation in women（WOMEN）trial. Circulation，2011，124：1239-1249.

［214］Gulati M，Arnsdorf MF，Shaw LJ，et al.Prognostic value of the duke treadmill score in asymptomatic women. Am J Cardiol，2005，96：369-375.

［215］Bourque JM，Holland BH，Watson DD，et al.Achieving an exercise workload of≥10 metabolic equivalents predicts a very low risk of inducible ischemia：does myocardial perfusion imaging have a role？J Am Coll Cardiol，2009，54：538-45.

［216］Gulati M，Black HR，Shaw LJ，et al.The prognostic value of a nomogram for exercise capacity in women.N Engl J Med，2005，353：468-475.

［217］Gupta S，Rohatgi A，Ayers CR，et al.Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality.Circulation，2011，123：1377-1383.

［218］Kligfield P，Lauer MS.Exercise electrocardiogram testing：beyond the ST segment.Circulation 2006，114：2070-82.

［219］Gulati M，Shaw LJ，Thisted RA，et al.Heart rate response to exercise stress testing in asymptomatic women：the st.James women take heart project.Circulation，2010，122：130-137.

［220］Adabag AS，Grandits GA，Prineas RJ，et al.Relation of heart rate parameters during exercise test to sudden death and all-cause mortality in asymptomatic men.Am J Cardiol，2008，101：1437-1443.

［221］Girotra S，Keelan M，Weinstein AR，et al.Relation of heart rate response to exercise with prognosis and atherosclerotic progression after coronary artery bypass grafting.Am J Cardiol，2009，103：1386-1390.

［222］Gera N，Taillon LA，Ward RP.Usefulness of abnormal heart rate recovery on exercise stress testing to predict high-risk findings on single-photon emissioncomputed tomography myocardial perfusion imaging in men.Am J Cardiol，2009，103：611-614.

［223］Lakkireddy DR，Bhakkad J，Korlakunta HL，et al.Prognostoc value of the Duke treadmill score in diabetic patients.An Heart J，2005，150：516-521.

［224］Lauer MS，Pothier CE，Magid DJ，et al.An externally validated model for predicting Long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal ectrocardiogram.Ann Intern Med，2007，147：821-828.

［225］Kohli P，Gulati M.Exercise stress testing in women：going back to the basics.Circulation，2010，122：2570-680.

［226］Sharma K，Kohli P et al，An Update on Exercise Stress Testing.Curr Probl Cardiol，2012，193-194.

［227］Budoff MJ，Cohen MC，Manning WJ，et al.ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance：a report of the American College of Cardiology Foundation/ American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol，2005，46：383-402.

［228］Zhi-hui Hou，Bin Lu，MD，Yang Gao，et al.Prognostic Value of Coronary CT Angiography and Calcium Score for Major Adverse Cardiac Events in Outpatients.J Am Coll Cardiol Imag，2012，5：990-9.

［229］Minghua Li，Jiayin Zhang，Jingwei Pan，Zhigang Lu.coronary Total Occlusion lesions：Linear Intrathrombus Enhancement at CT Predicts Better Outcome of Percutaneous Coronary Intervention.Radiology，2013，2（266）：443-451.

［230］Pugliese F，Weustink AC，Van Mieghem C，et al.Dual source coronary computed tomography angiography for detecting in-stent restenosis.，2008，94：848-854.

［231］Pflederer T，Marwan M，Renz A，et al.Noninvasive Assessment of Coronary In-Stent Restenosis by Dual-Source Computed Tomography.The Am J Cardiol，2009，103：812-817.

［232］Weustink AC，Nieman K，Pugliese F，et al.Diagnostic accuracy of computed tomography angiography in patients after bypass grafting：comparison with invasive coronary angiography.JACC Cardiovasc Imaging，2009，2：816-824.

［233］Laynez-Carnicero A，Estornell-Erill J，Trigo-Bautista A，et al.Non-invasive assessment of coronary artery bypass grafts and native coronary arteries using 64-slice computed tomography：comparison with invasive coronary angiography.Rev Esp Cardiol，2010，63：161-169.

［234］Bluemke DA，Achenbach S，Budoff M，et al.Noninvasive coronary artery imaging：magnetic resonance angiography and multidetector computed tomography angiography：a scientific statement from the American Heart Association Committee on Cardiovascular Imagingand Intervention of the Council on Cardiovascular Radiology and Intervention，and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young. Circulation，2008，118：586-606.

［235］Abdulla J，Abildstrom SZ，Gotzsche O，Christensen E，Kober L，Torp-Pedersen C.64-Multislice detector computed tomography coronary angiography as potential alternative to conventional coronary angiography：a systematic review and meta-analysis.Eur Heart J，2007，28：3042-3050.

［236］Vanhoenacker PK，Heijenbrok-Kal MH，Van Heste R，et al.Diagnostic performance of multidetector CT angiography for assessment of coronary artery disease：meta-analysis.Radiology，2007，244：419-428.

［237］Hoffmann U，Bamberg F，Chae CU，et al.Coronary computed tomography angiography for early triage of patients with acute chest pain：the ROMICAT（Rule Out Myocardial Infarction using Computer Assisted Tomography）trial.J Am Coll Cardiol，2009，53：1642-1650.

［238］Hoffmann U，Nagurney JT，Moselewski F，et al.Coronary multidetector computed tomography in the assessment of patients with acute chest pain.Circulation，2006，114：2251-2260.

［239］Goldstein JA，Gallagher MJ，O’Neill WW，Ross MA，O’Neil BJ，Raff GL.A randomized controlled trial of multislice coronary computed tomography for evaluation of acute chest pain.J Am Coll Cardiol，2007，49：863-871.

［240］Hachamovitch R，Di Carli MF.Methods and limitations of assessing new noninvasive tests：Part Ⅱ：outcomesbased validation and reliability assessment of noninvasive testing.Circulation，2008，117：2793-2801.

［241］中华放射学杂志心脏冠状动脉多排CT临床应用协作组.心脏冠状动脉多排CT临床应用专家共识：中华放射学杂志，2011，45（1）：9-17.

［242］Hyafil F，Cornily JC，Feig JE，et al.Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography.Nat Med，2007，13：636-641.

［243］Hyafil F，Cornily JC，Rudd JH，Machac J，Feldman LJ，Fayad ZA.Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177：a comparison with 18F-FDG PET/CT and histology.J Nucl Med，2009，50：959-965.

［244］Braunwald E.Noninvasive detection of vulnerable coronary plaques.Locking the barn door before the horse is stolen.J Am Coll Cardiol，2009，54：58-59.

［245］Motoyama S，Kondo T，Sarai M，et al.Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes.J Am Coll Cardiol，2007，50：319-326.

［246］赵世华，蒋世良，陆敏杰.心血管病磁共振诊断学.北京：人民军医出版社，2011.

［247］赵世华.冠心病与磁共振成像/冠心病影像学诊断（丛书主编　胡大一）.北京：北京大学医学出版社，2009.

［248］赵世华.磁共振成像在冠心病诊断中应用.临床荟萃2009，24（19）：1675-1677.

［249］赵世华，冯敢生，蒋世良，等.磁共振成像在异位心脏移植中的应用价值.中华老年心脑血管病杂志，2008，10（5）：337-340.

［250］赵世华.重视心血管病影像学方法的优势互补.中华放射学杂志，2008，42：901-902.

［251］赵世华.心血管影像学检查的合理应用.中华全科医师杂志，2008，7（1）：7-9.

［252］Lu M，Zhao S，Liu Q，et al.Transplantation with autologous mesenchymal stem cells after acute myocardial infarction evaluated by magnetic resonance imaging：an experimental study.J Thorac Imaging，2012，27：125-35.

［253］Lu M，Zhao S，Yin G，et al.T1 mapping for detection of left ventricular myocardial fibrosis in hypertrophic cardiomyopathy：A preliminary study.Eur J Radiol，2013，82（5）：e225-231.

［254］Yin G，Zhao S，Lu M，et al.Assessment of left ventricular myocardial scar in coronary artery disease by a threedimensional MR imaging technique.J Magn Reson Imaging，2012.doi：10.1002/jmri.23962.

［255］Ma N，Cheng H，Lu M，Jiang S，Yin G，Zhao S.Cardiac magnetic resonance imaging in arrhythmogenic right ventricular cardiomyopathy：correlation to the QRS dispersion.Magn Reson Imaging，2012，30：1454-1460.

［256］Liu Qiong，Zhao Shihua，Yan Chaowu，Myocardial viability in chronic ischemic heart disease：Comparison of delayed enhancement magnetic resonance imaging with 18F-Fluorodeoxyglucose single photon emission computed tomography.Nuclear Medicine Communication，2009，30：610-616.

［257］赵世华，闫朝武，杨敏福，等.磁共振心肌灌注延迟增强与核素心肌灌注/代谢显像识别存活心肌对比研究.中华心血管病杂志，2006，34（12）：1072-1076.

［258］王莉，朱海云，林琳，等.DSA冠状动脉狭窄与MRI相应供血区心肌缺血、坏死程度的对比分析.临床放射学杂志，2007，26（1）：30-33.

［259］赵世华.缺血性心脏病影像学诊断方法及其应用价值.影像诊断与介入治疗，2007，5：43.

［260］赵世华.心脏CT和MRI如何选择（述评）.中华放射学杂志，2009，43（9）：901-902.

［261］陆敏杰，赵世华，张普洪，等.时间调整敏感度编码与全局自动校准部分并行采集技术在心功能评价中的比较［J］.中华放射学杂志，2007，41（1）：10-13.

［262］陆敏杰，赵世华，蒋世良，等.磁共振成像在致心律不齐性右室型心肌病的诊断价值［J］.中华心血管病杂志，2006，34（12）：1077-1080.

［263］陆敏杰，赵世华，钱海燕，等.MRI评价骨髓间质干细胞治疗猪急性心肌梗死效果的实验研究［J］.中华放射学杂志，2008，42（2）：201-205.

［264］陆敏杰，赵世华.MR并行采集技术及其在心脏MR检查中的应用［J］.中华放射学杂志，2008，42（12）：1345-1347.

［265］陆敏杰，赵世华，刘盛，等.磁共振成像对冠心病陈旧性心肌梗死所致心功能不全的诊断及干细胞移植疗效评价的应用［J］.中华心血管病杂志，2008，36（11）：969-974.

［266］陆敏杰，赵世华，宋鹏等.MRI对急性心肌梗死后不同心脏状态下干细胞移植后体内再分布与疗效评价的动物实验研究［J］.中华放射学杂志，2011，45（7）：678-684.

［267］陆敏杰，赵世华，蒋世良，等.主动脉病变MR检查的序列选择和程序优化［J］.中华放射学杂志，2006，40（11）：1213-1218.

［268］陆敏杰，赵世华，宋鹏，等.磁共振成像对猪不同心脏状态下经冠状动脉干细胞移植后体内再分布的评价［J］.中华心血管病杂志，2010，38（11）：1014-1018.

［269］陆敏杰，赵世华，蒋世良，等.中国人心脏房室腔内径及左右心室功能正常参据的MRI研究［J］.中华放射学杂志，2011，45（10）：924-928.

［270］陆敏杰，赵世华.磁共振在复杂先天性心脏病诊断中的价值［J］.心血管病学进展，2010，31（5）：652-655.

［271］Bettencourt N，Chiribiri A，Schuster A，et al.Cardiac magnetic resonance myocardial perfusion imaging for detection of functionally significant obstructive coronary artery disease：A prospective study.Int J Cardiol，2012.

［272］Beek AM，van Rossum AC.Use of cardiovascular magnetic resonance imaging in the assessment of left ventricular function，scar and viability in patients with ischaemic cardiomyopathy and chronic myocardial infarction.Heart，2010，96：1494-1501.

［273］Hachamovitch R，Nutter B，Hlatky MA，et al.Patient management after noninvasive cardiac imaging results from SPARC（Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease）.J Am Coll Cardiol，2012，59：462-474.

［274］Jaarsma C，Leiner T，Bekkers SC，et al.Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography，cardiac magnetic resonance，and positron emission tomography imaging for the detection of obstructive coronary artery disease：a meta-analysis.J Am Coll Cardiol，2012，59：1719-1728.

［275］Jogiya R，Kozerke S，Morton G，et al.Validation of dynamic 3-dimensional whole heart magnetic resonance myocardial perfusion imaging against fractional flow reserve for the detection of significant coronary artery disease.J Am Coll Cardiol，2012，60：756-765.

［276］Liga R，Neglia D.Coronary atherosclerosis and quantitative myocardial perfusion：a relationship beyond stenosis.J Am Coll Cardiol，2012，59：1407-1408.

［277］de Jong MC，Genders TS，Hunink MG.“Reply to letter to the editor re：diagnostic performance of stress myocardial perfusion imaging for coronary artery disease：a systematic review and meta-analysis”.Eur Radiol，2013，23：349-350.

［278］Manka R，Paetsch I，Kozerke S，et al.Whole-heart dynamic three-dimensional magnetic resonance perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve：determination of volumetric myocardial ischaemic burden and coronary lesion location.Eur Heart，J 2012，33：2016-2024.

［279］Morton G，Chiribiri A，Ishida M，et al.Quantification of absolute myocardial perfusion in patients with coronary artery disease：comparison between cardiovascular magnetic resonance and positron emission tomography.J Am Coll Cardiol，2012，60：1546-1555.

［280］Khodarahmi I，Mobasheri H，Firouzi M.The effect of 2.1T static magnetic field on astrocyte viability and morphology.Magn Reson Imaging，2010，28：903-909.

［281］Simor T，Suranyi P，Ruzsics B，et al.Percent infarct mapping for delayed contrast enhancement magnetic resonance imaging to quantify myocardial viability by Gd（DTPA）.J Magn Reson Imaging，2010，32：859-868.

［282］Schuster A，Paul M，Bettencourt N，et al.Cardiovascular magnetic resonance myocardial feature tracking for quantitative viability assessment in ischemic cardiomyopathy.Int J Cardiol，2011，166（2）：413-420.

［283］Schwitter J，Wacker CM，Wilke N，et al.MR-IMPACT Ⅱ：Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial：perfusion-cardiac magnetic resonance vs.singlephoton emission computed tomography for the detection of coronary artery disease：a comparative multicentre，multivendor trial.Eur Heart J，2013，34（10）：775-781.

［284］Schwitter J，Arai AE.Assessment of cardiac ischaemia and viability：role of cardiovascular magnetic resonance. Eur Heart J，2011，32：799-809.

［285］Gaibazzi N，Rigo F，Lorenzoni V，et al.Comparative prediction of cardiac events by wall motion，wall motion plus coronary flow reserve，or myocardial perfusion analysis：a multicenter study of contrast stress echocardiography.JACC Cardiovasc Imaging，2013，6：1-12.

［286］Gerbaud E，Faury A，Coste P，et al.Comparative analysis of cardiac magnetic resonance viability indexes to predict functional recovery after successful percutaneous coronary intervention in acute myocardial infarction. Am J Cardiol，2010，105：598-604.

［287］Jahnke C，Paetsch I，Achenbach S，et al.Coronary MR imaging：breath-hold capability and patterns，coronary artery rest periods，and beta-blocker use.Radiology，2006，239（1）：71-78.

［288］Leiner T，Katsimaglis G，Yeh EN，et al.Correction for heart rate variability improves coronary magnetic resonance angiography.J Magn Reson Imaging，2005，22（4）：577-582.

［289］Sakuma H，Ichikawa Y，Suzawa N，et al.Assessment of coronary arteries with total study time of less than 30 minutes by using whole-heart coronary MR angiography.Radiology，2005，237（1）：316-321.

［290］Maintz D，Ozgun M，Hoffmeier A，et al.Selective coronary artery plaque visualization and differentiation by contrast-enhanced inversion prepared MRI.Eur Heart J，2006，27（14）：1732-1736.

［291］Priest AN，Ittrich H，Jahntz CL，et al.Investigation of atherosclerotic plaques with MRI at 3 T using ultrasmall superparamagnetic particles of iron oxide.Magn Reson Imaging，2006，24（10）：1287-1293.

［292］Schuijf JD，Bax JJ，Shaw LJ，et al.Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography.Am Heart J，2006，151（2）：404-411.

［293］Dewey M，Teige F，Schnapauff D，et al.Combination of free-breathing and breathhold steady-state free precession magnetic resonance angiography for detection of coronary artery stenoses.J Magn Reson Imaging，2006，23（5）：674-681.

［294］Fuster V，Fayad ZA，Moreno PR，et al.Atherothrombosis and high-risk plaque：Part Ⅱ：approaches by noninvasive computed tomographic/magnetic resonance imaging.J Am Coll Cardiol，2005，46（7）：1209-1218.

［295］刘新，赵锡海，程流泉，等.冠状动脉CT和MR血管成像诊断粥样硬化斑块和狭窄的对比研究.中华放射学杂志，2006，40（11）：1156-1160.

［296］贺毅，张兆琪，于薇，等.小剂量多巴酚丁胺负荷MRI与负荷超声心动图检测存活心肌的对比研究.中华放射线学杂志，2006，40（11）：1152-1155.

［297］Nijveldt R，Hofman MB，Hirsch A，et al.Assessment of microvascular obstruction and prediction of short-term remodeling after acute myocardial infarction：cardiac MR imaging study.Radiology，2009，250（2）：363-370.

［298］Klumpp B，Hoevelborn T，Fenchel M，et al.Magnetic resonance myocardial perfusion imaging-First experience at 3.0T.Eur J Radiol，2009，69（1）：165-172.

［299］Merkle N，Wöhrle J，Grebe O，et al.Assessment of myocardial perfusion for detection of coronary artery stenoses by steady-state，free-precession magnetic resonance first-pass imaging.Heart，2007，93（11）：1381-1385.

［300］Trindade ML，Caldas MA，Tsutsui JM，et al.Determination of size and transmural extent of acute myocardial infarction by real-time myocardial perfusion echocardiography：a comparison with magnetic resonance imaging. J Am Soc Echocardiogr，2007，20（2）：126-135.

［301］Schwitter J.Myocardial perfusion imaging by cardiac magnetic resonance.J Nucl Cardiol，2006，13（6）：841-854.

［302］Watkins S，Oldroyd KG，Frohwein S.Magnetic resonance myocardial perfusion imaging：a new era in the detection of reversible myocardial ischaemia.Heart，2007，93（1）：7-10.

［303］Bodí V，Sanchis J，López-Lereu MP，et al.Microvascular perfusion 1 week and 6 months after myocardial infarction by first-pass perfusion cardiovascular magnetic resonance imaging.Heart，2006，92（12）：1801-1807.

［304］Bandettini WP，Arai AE.Advances in clinical applications of cardiovascular magnetic resonance imaging. Heart，2008，94（11）：1485-1495.

［305］Cury RC，Shash K，Nagurney JT，et al.Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department.Circulation，2008，118（8）：837-844.

［306］Kim RJ，Albert TS，Wible JH，et al.Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction：an international，multicenter，double-blinded，randomized trial.Circulation，2008，117（5）：629-637.

［307］Selvanayagam JB，Cheng AS，Jerosch-Herold M，et al.Effect of distal embolization on myocardial perfusion reserve after percutaneous coronary intervention：a quantitative magnetic resonance perfusion study. Circulation，2007，116（13）：1458-1464.

［308］Muehling OM，Huber A，Cyran C，et al.The delay of contrast arrival in magnetic resonance first-pass perfusion imaging：a novel non-invasive parameter detecting collateral-dependent myocardium.Heart，2007，93（7）：842-847.

［309］Cheng AS，Pegg TJ，Karamitsos TD，et al.Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease：a comparison with 1.5-tesla.J Am Coll Cardiol，2007，49（25）：2440-2449.

［310］Gershlick AH，de Belder M，Chambers J，et al.Role of non-invasive imaging in the management of coronary artery disease：an assessment of likely change over the next 10 years.A report from the British Cardiovascular Society Working Group.Heart，2007，93（4）：423-431.

［311］Klem I，Heitner JF，Shah DJ，et al.Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging.J Am Coll Cardiol，2006，47（8）：1630-1638.

［312］Biagini E，van Geuns RJ，Baks T，et al.Comparison between contrast echocardiography and magnetic resonance imaging to predict improvement of myocardial function after primary coronary intervention.Am J Cardiol，2006，97（3）：361-366.

［313］Selvanayagam JB，Jerosch-Herold M，Porto I，et al.Resting myocardial blood flow is impaired in hibernating myocardium：a magnetic resonance study of quantitative perfusion assessment.Circulation，2005，112（21）：3289-3296.

［314］Bodí V，Sanchis J，López-Lereu MP，et al.Usefulness of a comprehensive cardiovascular magnetic resonance imaging assessment for predicting recovery of left ventricular wall motion in the setting of myocardial stunning. J Am Coll Cardiol，2005，46（9）：1747-1752.

［315］Mahnken AH，Koos R，Katoh M，et al.Assessment of myocardial viability in reperfused acute myocardial infarction using 16-slice computed tomography in comparison to magnetic resonance imaging.J Am Coll Cardiol.2005，45（12）：2042-2047.

［316］Ibrahim T，Nekolla SG，Hörnke M，et al.Quantitative measurement of infarct size by contrast-enhanced magnetic resonance imaging early after acute myocardial infarction：comparison with single-photon emission tomography using Tc99m-sestamibi.J Am Coll Cardiol，2005，45（4）：544-552.

［317］Lu M，Zhao S，Yin G，et al.T1 mapping for detection of left ventricular myocardial fibrosis in hypertrophic cardiomyopathy：a preliminary study.Eur J Radiol，2013，82（5）：e225-231.

［318］Lu M，Zhao S，Jiang S，et al.Fat Deposition in Dilated Cardiomyopathy Assessed by CMR.JACC Cardiovasc Imaging，2013 Jul 5.doi：pii：S1936-878X（13）00454-3.

［319］Lu M，Liu S，Zheng Z，et al.A pilot trial of autologous bone marrow mononuclear cell transplantation through grafting artery：A sub-study focused on segmental left ventricular function recovery and scar reduction.Int J Cardiol.2013 Mar 7.doi：pii：S0167-5273（13）00277-5.10.1016/j.ijcard.2013.01.217.

［320］Lu M，Zhao S，Liu Q，et al.Transplantation with autologous mesenchymal stem cells after acute myocardial infarction evaluated by magnetic resonance imaging：an experimental study.J Thorac Imaging.2012 Mar；27（2）：125-35.doi：10.1097/RTI.0b013e31820446fa.

［321］陆敏杰，赵世华，蒋世良，等.中国人心脏房室腔内径及左右心室功能正常参据的MRI研究.中华放射学杂志，2011，45（10）：924-928.

［322］陆敏杰，赵世华.2011心血管影像回眸.心血管病学进展，2012，33（2）：158-160.

［323］陆敏杰，赵世华，张普洪，等.时间调整敏感度编码与全局自动校准部分并行采集技术在心功能评价中的比较.中华放射学杂志，2007，41（1）：10-13.

［324］陆敏杰，赵世华，蒋世良，等.磁共振成像在致心律不齐性右室型心肌病的诊断价值.中华心血管病杂志，2006，34（12）：1077-1080.

［325］陆敏杰，赵世华.MR并行采集技术及其在心脏MR检查中的应用.中华放射学杂志，2008，42（12）：1345-1347.

［326］陆敏杰，赵世华，蒋世良，等.MR纵向弛豫时间定量成像评价肥厚型心肌病心肌纤维化的初步研究.中华放射学杂志，2013，47（5）：391-395.